Panel calls on FDA to review safety of opioid painkillers

July 13, 2017 by Carla K. Johnson
This Feb. 19, 2013 file photo shows hydrocodone-acetaminophen pills, also known as Vicodin, arranged for a photo at a pharmacy in Montpelier, Vt. On Thursday, July 13, 2017, the National Academies of Sciences, Engineering and Medicine released a report saying the U.S. Food and Drug Administration should review the safety and effectiveness of all opioid painkillers. (AP Photo/Toby Talbot, File)

The U.S. Food and Drug Administration should review the safety and effectiveness of all opioids, and consider the real-world impacts the powerful painkillers have, not only on patients, but also on families, crime and the demand for heroin.

That's the conclusion of a sweeping Thursday from the National Academies of Sciences, Engineering and Medicine. It urges the FDA to bolster a public health approach that already has resulted in one painkiller being pulled from the market. Last week, the maker of opioid painkiller Opana ER withdrew its drug at the FDA's request following a 2015 outbreak of HIV and hepatitis C in southern Indiana linked to sharing needles to inject the pills.

"Our recommendation is for a much more systematic approach, integrating decision-making into all aspects of opioid review and approval," said Dr. Aaron Kesselheim of Harvard Medical School, a member of the report committee. "It would be an ambitious undertaking."

The report details how two intertwining epidemics—prescription painkillers and heroin—led to the worst addiction crisis in U.S. history and provides a plan for turning back the tide of overdose deaths.

Prescribed, legal drugs are a gateway to illicit drugs for some, the report says. Other users start with pills diverted to the black market. Crush-resistant pills and other restrictions can have unintended consequences, shifting use to heroin and illicit fentanyl.

The epidemic's broad reach into rural and suburban America "has blurred the formerly distinct social boundary between use of prescribed opioids and use of heroin and other illegally manufactured ones," the report says.

The authors say it's possible to stem the crisis without denying opioids to patients whose doctors prescribe them responsibly. But long-term use of opioids by people with chronic pain should be discouraged because it increases dangers of overdose and addiction.

Requested by the FDA last year under the Obama administration, the report was greeted by FDA Commissioner Dr. Scott Gottlieb, a Trump appointee. Gottlieb said in a statement that the opioid epidemic is his "highest immediate priority" and he "was encouraged to see that many of (the) recommendations for the FDA are in areas where we've already made new commitments."

Still, no immediate review of opioids as a class of drugs is planned by the FDA, other than the agency's routine safety surveillance. Gottlieb said the FDA re-evaluates the safety of approved drugs with post-market information required from drugmakers and other sources.

"We will continue to consider what additional information is needed to ensure we have the right data to make important, science-based decisions," he said.

Beyond the FDA, the report recommends:

—Better access to treatment for opioid addiction, including use of medications such as buprenorphine, in settings including hospitals, prisons and treatment programs. (The revised Senate Republican health care bill released Thursday includes $45 billion for states to use for addiction treatment and other responses to the crisis, a boost over the $2 billion in the initial bill.)

—Year-round programs that allow people to return unused opioids to any pharmacy at any time, rather than only at occasional events. Some pharmacies, including Walgreens, have installed kiosks where people can get rid of pills.

—Insurers pay for pain control that goes beyond opioids to include non-drug treatment. The report doesn't specify which treatments insurers should cover, but does outline what early evidence exists for acupuncture, physical therapy, cognitive-behavioral therapy and mindfulness meditation, calling them "powerful tools."

—More research on the nature of pain and dependency on opioids and development of new non-addictive treatments.

Explore further: New report presents national strategy to reduce opioid epidemic

Related Stories

New report presents national strategy to reduce opioid epidemic

July 13, 2017
Years of sustained and coordinated efforts will be required to contain and reverse the harmful societal effects of the prescription and illicit opioid epidemics, which are intertwined and getting worse, says a new report ...

Investigators examine the relationship between pain and opioid abuse

June 12, 2017
The drug overdose epidemic is largely driven by opioids, which continue to be prescribed for chronic pain despite recommendations to use non-opioids for most cases. A new review published in the British Journal of Pharmacology ...

When is an opioid safe to take?

June 26, 2017
(HealthDay)—Many people in pain are apprehensive about taking an opioid painkiller to ease their suffering, and rightfully so.

Opioid dependence can start in just a few days

March 16, 2017
(HealthDay)—Doctors who limit the supply of opioids they prescribe to three days or less may help patients avoid the dangers of dependence and addiction, a new study suggests.

Americans favor treatment, not enforcement, to address opioid crisis

May 23, 2017
Many Americans have been directly touched by the opioid crisis—more than a quarter of Americans and more than a third of millennials, report knowing someone who has been addicted to opioids or prescription painkillers. ...

Ohio sues five drugmakers over role in opioid crisis

May 31, 2017
The US state of Ohio on Wednesday sued five major producers of prescription opioid medications, accusing them of lying about the deadly risks the painkillers—at the center of a nationwide addiction crisis—posed to public ...

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.